Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
Italy
Digestive Disease Center, Fondazione Policlinico Univesitario A. Gemelli IRCCS, Rome